---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-032433"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2025-08-25T23:59:59+00:00"
generated_at: "2026-05-17T10:12:10.360619+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech reports mOS 39.3 months in VERSATILE-002 Phase 2 vs 17.9 months standard of care

## Summary
- Median overall survival of 39.3 months (lower bound 23.9) in CPS≥1 patients with HPV16+ HNSCC; standard pembrolizumab ± chemo mOS is 17.9 months.
- 53 patients enrolled; no discontinuations due to treatment-related adverse events.
- Phase 3 VERSATILE-003 trial is underway based on these results.
- Durable multifunctional HPV16-specific CD8+ T cells induced by PDS0101 observed across demographics.
- Full data set to be published later this year.

## SEC filing metadata
- accession: 0001140361-25-032433
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2025-08-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036125032433/0001140361-25-032433-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036125032433/ef20054394_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-032433
- JSON: https://secwatch.observer/filing/0001140361-25-032433.json
- Plain text: https://secwatch.observer/filing/0001140361-25-032433.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.